Development and validation of an HPLC method for determination of carbamazepine in human plasma and applications to a therapeutic drug monitoring study

Abstract

Background and Aims: Carbamazepine (CBZ) is an antiepileptic drug, which is prescribed as a first-line drug for the treatment of partial and generalized tonic–clonic epileptic seizures. The aim of this study was to develop and validate a simple, fastand reliable HPLC method for the determination of carbamazepine in human plasma.Methods: Chlorpromazine (CPR) was used as an internal standard. The separation was conducted with a C18 reverse-phasecolumn (150x3.9 mm, 5 µm) at 30°C, using a mobile phase prepared with 20 mM KH2PO4, acetonitrile and methanol (6:3:1,v/v/v) by isocratic elution.Results: The method was linear between 0.5 and 40 µg/mL, determined by 10 individual calibration points. Total run time was≤ 5 mins. Accuracy (RE%) values were determined between (-5.6) and 3.6%, and precision was determined at ≤4.2%. Limit ofdetection (LOD) was 0.04 µg/mL. The robustness test results of the method showed good values. Plasma CBZ of (n=30) thosereceiving CBZ quantities ranging from 0.2 to 1.2 g/day were measured with this method, and following analyses of their concentrations were found to be between 0.1 and 11.4 µg/mL (6.2±2.4 µg/mL). While all plasma sample analyses were appliedproperly, it was observed that 16 (53.3%) of the plasma samples had CBZ lower than the recommended range. In addition tothat, female patient plasma-CBZ levels were found significantly higher than male plasma contents (p